Neurocrine Biosciences, Inc. annual gross profit for fiscal 2025 was $2.8 billion, an increase of 21.0% from $2.3 billion in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| Gross Profit (annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gross Profit | $2.8B | $2.3B | $1.8B | $1.5B | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Gross Profit (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit | $801M | $788M | $781M | $676M | $563M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More NBIX metrics: Revenue · Operating Income · Net Income · EPS · Free Cash Flow
All NBIX financial statements → Interactive NBIX charts →
About TickerBase · Data methodology & sources